…

The clinical scenario described in this case highlights a therapeutic dilemma that nephrologists and rheumatologists face with increasing frequency as the population of patients with advanced chronic kidney disease and gout continues to grow. Hyperuricemia is exceptionally common in patients with stage 5 chronic kidney disease, arising from reduced renal clearance of uric acid, chronic low-grade inflammation associated with dialysis, and the metabolic comorbidities that frequently accompany end-stage kidney disease. Yet the very therapies that form the backbone of acute gout management are constrained in this population. Nonsteroidal anti-inflammatory drugs carry risks of further renal injury, gastrointestinal bleeding, and cardiovascular events, all of which were directly relevant to this patient, who had recently survived a massive gastrointestinal bleed with hemorrhagic shock and had established coronary artery disease requiring post-surgical antiplatelet therapy. Colchicine requires dose adjustment in renal impairment and can cause cumulative toxicity in patients who cannot clear the drug efficiently. Glucocorticoids, while often used as a fallback, can worsen glycemic control in a patient with impaired glucose tolerance, exacerbate fluid retention, and complicate infection management in someone already being treated for pulmonary infection. This convergence of contraindications is precisely the situation in which interleukin-1β–directed therapy becomes an appealing option, and it explains why the treating team considered firsekibart despite the absence of dedicated dialysis-specific evidence.

The interleukin-1β pathway occupies a central position in the pathogenesis of acute gouty inflammation. Monosodium urate crystals deposited in joints act as danger signals that activate the inflammasome, a multiprotein intracellular complex that processes pro–interleukin-1β into its mature, secreted form. Once released, interleukin-1β drives the vasodilation, endothelial activation, neutrophil recruitment, and pain sensitization that characterize the excruciatingly painful flare typical of gout. Blocking this single upstream cytokine can therefore interrupt much of the inflammatory cascade at once, which is consistent with the rapid pain relief observed in clinical trials of interleukin-1β inhibitors. Firsekibart, as a fully human IgG4 monoclonal antibody, binds interleukin-1β directly and neutralizes its activity. The fully human design is intended to reduce the risk of immunogenicity-related reactions compared with engineered or partially non-human antibodies, an important consideration given that repeated administration may be needed across a patient’s lifetime of recurrent flares.

The pharmacokinetic behavior of monoclonal antibodies provides important context for interpreting the timing observations in this case. Unlike small-molecule drugs, monoclonal antibodies are large proteins that are not meaningfully removed by conventional hemodialysis, which relies on diffusion and convection across a semipermeable membrane with a molecular weight cutoff far below the roughly 150 kilodalton mass of an intact IgG molecule. Antibodies distributed in the plasma and interstitial compartments are also protected from elimination by cellular catabolism and recycling mechanisms, notably the neonatal Fc receptor, which salvages IgG from lysosomal degradation and contributes to the characteristically long half-lives of this drug class, often measured in weeks. On theoretical grounds, therefore, one would not expect a single hemodialysis session to substantially reduce firsekibart exposure, and the absence of pain rebound after dialysis in this patient is consistent with that expectation. Nevertheless, the authors appropriately emphasize that no pre- or post-dialysis concentration measurements were obtained, so the theoretical argument cannot be converted into demonstrated pharmacokinetic fact from this report alone. Directly measured drug levels before and after dialysis sessions would be needed to confirm that dialysis does not materially alter exposure, and such data would be valuable given the complete absence of dedicated pharmacokinetic information in the product label for this population.

The temporal sequence documented in the case deserves careful reading. Pain relief was recorded six to seven hours after firsekibart administration, which is biologically plausible for an interleukin-1β blockade strategy, since neutralizing the cytokine can produce relatively rapid anti-inflammatory effects. However, the patient had also received tramadol and topical flurbiprofen within the hour preceding the documented improvement, and both agents could plausibly contribute to analgesia on that timescale. Tramadol acts centrally on opioid and monoaminergic pathways and can reduce pain perception within hours of dosing, while topical nonsteroidal anti-inflammatory agents can provide localized symptomatic relief. This overlap of interventions is an almost unavoidable feature of clinical care in a patient in severe pain, but it means that the observed improvement cannot be attributed to firsekibart with confidence. The authors’ transparent acknowledgment of this confounding is a strength of the report, and it illustrates a general principle in single-patient observations: temporality is necessary but not sufficient for causal inference, and co-administered therapies must always be considered as alternative explanations.

Equally instructive is what happened over the subsequent weeks. No gout flare recurred through the thirty-five-day follow-up window, which is encouraging given that the patient had experienced flares roughly monthly before this hospitalization. However, the follow-up period was not event-free. The patient developed biliary symptoms, plausibly related to his known gallstones, and a febrile episode with suspected catheter-related bloodstream infection. Both events had plausible alternative explanations independent of firsekibart, but their occurrence underscores a genuine safety consideration for the entire class of interleukin-1β inhibitors. Interleukin-1β is a key component of innate immune defense, and pharmacological blockade of the pathway has been associated with increased susceptibility to infections in other therapeutic contexts. A patient on maintenance hemodialysis is already at elevated infection risk through vascular access, uremia-related immune dysfunction, and recent intensive care admission with invasive devices and broad-spectrum antimicrobial exposure. Disentangling the contribution of cytokine blockade from these background risks in a single patient is essentially impossible, and the authors correctly characterized the relationships as uncertain.

The broader evidence landscape for interleukin-1–directed therapy in gout provides useful perspective on where this case fits. Inhibitors of the interleukin-1 pathway, including agents that block interleukin-1β directly and others that antagonize the interleukin-1 receptor, have been studied in acute gout for well over a decade, with randomized trials demonstrating rapid pain relief in patients for whom conventional therapy was unsuitable, contraindicated, or ineffective. Clinical guidance documents in rheumatology have acknowledged interleukin-1 inhibition as an option for flares in which first-line agents cannot be used. What has been persistently missing is evidence in the dialysis population, because pivotal trials commonly exclude patients with advanced kidney disease out of concern for safety, pharmacokinetic uncertainty, and confounding comorbidity. The consequence is a circular problem: dialysis patients are excluded from trials because data are lacking, and data remain lacking because dialysis patients are excluded. Case reports such as this one, while individually weak in inferential terms, are often the first signals that accumulate to justify formal pharmacokinetic and safety studies in excluded populations.

Several methodological limitations inherent to this report merit emphasis for readers weighing its implications. The retrospective design means that the timing of assessments, including visual analogue scale pain scoring, was dictated by routine clinical care rather than a prespecified protocol, introducing potential measurement imprecision. The absence of serum urate trajectory data during the flare limits interpretation, since the reported value of 506 micromoles per liter reflects the inflammatory and renal context rather than a controlled baseline. The lack of histopathology for the previously excised elbow lesion leaves the diagnosis of gouty tophus based on imaging and clinical pattern rather than tissue confirmation, although the polyarticular presentation, recurrent flare history, and markedly elevated uric acid make the clinical diagnosis reasonable. Finally, the co-administration of multiple analgesic and anti-inflammatory agents around the time of firsekibart dosing, as noted above, prevents isolation of the drug’s specific contribution to symptom resolution.

For clinicians, the practical takeaway is not that firsekibart is established therapy for gout in hemodialysis patients, but that this case documents a real-world instance of its use in exactly the kind of multimorbid patient in whom conventional options are constrained. The observations—apparent early pain relief, no rebound after dialysis, no immediate hypersensitivity reaction, and no flare recurrence over five weeks—are consistent with theoretical expectations for an IgG4 antibody in this setting, but they are observations, not proof. Future studies that directly measure firsekibart concentrations across dialysis sessions, systematically capture infection and other adverse events, and compare interleukin-1β blockade against optimized conventional regimens in dialysis patients would convert this anecdote into actionable evidence. Until such data exist, decisions in comparable patients will continue to rest on individualized risk-benefit assessment, multidisciplinary judgment, and the careful documentation of outcomes that reports like this one provide.

Subject of Research: …

Article Title: Use of firsekibart for acute gouty arthritis in a maintenance hemodialysis patient with multiple high-risk comorbidities: a case report

Article References: Use of firsekibart for acute gouty arthritis in a maintenance hemodialysis patient with multiple high-risk comorbidities: a case report. (n.d.). https://doi.org/10.3389/fphar.2026.1928098

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1928098

Keywords: firsekibart, acute, gouty, arthritis, maintenance, hemodialysis, patient, multiple, high-risk, comorbidities, case, report